The population of women in Duluth over 45 is estimated by the U.S. Census Bureau at 28,000.

Women most affected by menopausal symptoms are between 45 and 64. My mother, aunts, and grandmother are all of this age and all have weathered their menopausal changes, some with the aid of prescription hormone replacement therapy.

A shared experience is of a healthy, shift-working woman, 45 years old, struggling with significant night sweats and insomnia for three months. She makes an appointment with her primary-care provider, who has been seeing her regularly for health care for the last few years, since after the birth of her daughter. She previously had regular care with her OB/GYN doctor but felt too old for her follow-up routine visits. So she transitioned to a local primary-care provider. At this visit, she hoped to receive some aid for her bothersome symptoms.

I dont have the luxury to be this tired all the time from not sleeping due to these horrible night sweats, she said to her doctor. I need to be efficient at work so I can provide for my family. Is there something I can take or do?

Her primary replied, I have to refer you to an OB/GYN, because I do not have the expertise to manage patients with hormone replacement therapy, which is a treatment that can help you.

She is frustrated because she took off work for this visit and now has to make another visit in the OB/GYN office in three weeks and has an additional drive of 35 minutes. But she complies.

At her next visit, she is struck with how old she feels, surrounded in the waiting room by young expecting mothers and their buzzing children. She meets with the OB/GYN provider, who spends a brief seven minutes with her, and she leaves feeling very comfortable with a new prescription of hormone replacement therapy.

The problem is this common treatment of hormone replacement therapy, or HRT, is not routinely instructed to primary-care providers in their mandatory continuing-education requirements, particularly in low-risk women. Primary-care providers are required to have continued education as part of their licensure to practice medicine.

These providers serving female patients include medical doctors, nurse practitioners, advanced-practice registered nurses, and physician assistants. This problem leads to increased costs and referrals for low-risk patients and a loss of revenue for providers who have the capacity to manage this highly effective and safe therapy for close to half of their patient population.

As a womens-health nurse practitioner, I have heard this common story from many female patients, and it is time for the health care system to listen. All primary-care providers need regular, mandatory continuing education on hormone replacement therapy treatments. This mandatory education should include the large body of evidence that supports the safe use of HRT in menopausal women and the important risk factors when HRT is not appropriate.

HRT can be counseled, prescribed, and managed in low-risk women by primary-care providers.

Regionally, the practice of managing HRT is diverse and is very typical practice in urban settings while much less common practice in rural areas where primary-care providers are pivotal.

My primary-care colleagues continue to ask how to treat female patients who have multiple high-risk factors and who shouldnt be on HRT. My rebuttal is that their keen knowledge is correct: HRT is likely not the treatment for these female patients. A referral to an expert in womens health is highly encouraged for high-risk women. The population of high-risk women is typically amongst younger ages or is found during pregnancy or through routine surveillance in all care settings.

With mandatory continuing education for primary-care providers in managing safe hormone replacement therapy for women, their confidence in the medications and the management of these low-risk women will increase, along with provider satisfaction from patients.

Kelsey Thompson of Duluth is a womens-health nurse practitioner in Minneapolis. She received a bachelors degree in nursing from the College of St. Scholastica. She earned a masters in womens health and a doctorate in nursing from Duke University in North Carolina.

See more here:
Nurse's View Column: Health care system failing the women in our families - Duluth News Tribune

Menopause happens due to a natural decline in reproductive hormones when a woman reaches her 40s or 50s and leads to hormonal and biological changes in the body including weight gain and hot flashes. The symptoms of menopause are commonly treated through hormone replacement therapy (HRT) which helps balance the hormonal levels in menopausal women.

During menopause, the ovaries make less estrogen and more progesterone which are hormones that control the monthly cycle. These hormones affect the heart, bones and vagina and the process of replacing them with the lab-made versions is called hormone replacement therapy. It helps provide relief from hot flashes and sweating, aids better sleep and reduces vaginal dryness and itching. The therapy also reduces the risk of heart diseases, osteoporosis and dementia among women.

According to Breastcancer.org, women who have undergone HRT are at an increased risk of breast cancer. There are two types of HRT- Estrogen HRT containing only estrogen and Combination HRT combining estrogen and progesterone and both have different effects on breast cancer. Though both types of therapy (estrogen and progesterone combined and estrogen alone) increase the risk of breast cancer, the risk is higher in case of combined therapy.

According to a Lancet Study, findings on breast cancer risk associated with HRT highlight that, the risk of developing the disease is twice as much in those who have undergone HRT therapies for 5-14 years as compared to those below 5 years.

So, what are the precautionary measures one should take in such a condition?

1. While opting for HRT, it is also critical to assess the risk of breast cancer through medical consultation for altering the dosage or duration of the therapy basis the risk.

2. Factors such as individual characteristics, risk factors, and severity of menopause symptoms, should be considered while weighing the pros and cons of HRT.

3. Patients diagnosed with breast cancer or having tested positive with an abnormal breast cancer gene should not opt for HRT because they can cause them to develop and grow.

4. For those who cannot undergo HRT, non-hormonal alternatives such as dietary changes, exercise, weight management, acupuncture or meditation can work for relieving symptoms of menopause.

Lifestyle changes

Apart from those who have undergone HRT and are at greater risk of breast cancer, all women should take care of their health through lifestyle alterations for reducing risk of breast cancer by:

* Consuming a healthy and balanced diet

* Engaging in adequate physical exercise

* Keeping your weight in control

* Limiting smoking and consumption of alcohol

* Avoiding exposure to radiation such as CT

* Avoiding environmental pollution

* Hormonal contraception including birth control pills can increase the risk of breast cancer and one must be careful while taking them

(Author Dr Rajeev Agarwal is Director, Cancer Institute, Medanta Hospitals)

Follow @News18Lifestyle for more

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you in real time.

Link:
Hormone Replacement Therapy Used for Menopause can be Linked to Increased Breast Cancer Risk - News18

Oct 31, 2019 10:53 AM EDT

Libido is the jargon for sex drive.The natural sex drive varies from individual to individual. Having a low sex drive is not a medical or psychological problem. As mentioned, it varies with each person. However, if you wish to increase your libido, there are numerous pills in the market. The backside of this method is the long list of side-effects in using those pills from heart diseases to eye-related problems. To avoid this, it is best to naturally boost your libido.

Sex drive is deeply linked with your mental health. A stressed or anxious individual might not be able to have an active personal life. A high level of anxiety is the most common cause of lower sex drive in many. According to a general review conducted in 2017, young men have mentioned anxiety and depression as their causes of the problem. There could be numerous reasons for those mental health problems. Starting from taking therapies to having a hobby, there is a number of methods to deal with your mental health.

Just like mental health, certain physical health can also cause loss of sex drive. Many diseases, which affect hormone levels can cause reduced libido. In such a situation, dealing with those hormone problems would automatically improve your libido. In certain cases, hormone replacement therapy or hormone treatmentswill be usefulin the long run rather than pills. Talk to your doctor immediately instead of going for some online hormone pills or supplements.

Your sexual desire is deeply connected with the intimacy of your relationship. You would need an intimate relationship to get the desire. It is common to have a lesser drive in relationships that last for a very long time. In such cases, it is best to increase intimacy and rekindle love. Plan date nights, spend quality time together, take a vacation and so on. If required, there are couples' therapists who can help you out in this process.

Goodnight sleep is very essential for energy and mood. In the same manner, good sleep can also lead to better libido. Just a night of disturbed sleep would not cause any tremendous effect on your libido. However, if you are having disturbed sleep for a long time, you might be suffering from insomnia.

Insomnia is not just about lack of sleep. It can cause many related problems like weight change, depression, chronic fatigue, reduced concentration and so on. If you have insomnia, take natural solutions to solve the problem by reducing caffeine content, having a sleep cycle, keeping active throughout the day and so on. If depression, phobia, anxiety or other mental problem is the root cause for insomnia, talk to your therapist immediately.

Do you know that libido is not just a mood-related effect? Hormones secreted by your body plays an important role in your sex-drive. Many food items can cause serious effects on hormone levels. The best way to improve libido is by reducing bad cholesterol for your diet. You need a diet, which is rich in vegetables, lean protein, and good fat. Reduce sugar and carbohydrates. Starving can reduce your libido tremendously. Dieting is not starving. You should eat the required amount of food to keep you full and at the same time, you should have a balanced diet.

There are numerous supplements, which are promoted to increase your libido. However, it is always best to go with herbal sources before you choose chemical-riddled supplements. No matter how expensive the supplement might be, there would be additive chemicals and preservatives, which can cause other problems.According to a studyconducted in 2015, a few herbal products and spices are known to improve libido and are used since ancient civilization for this purpose. Top herbal items are ginseng, Tribulus, mac, gingko, and others.

Lower sex drive is caused due to reduced body confidence, diabetes-related problems and so on. All these roots from not having a healthy weight. Being skinny thin is not recommended. You need to keep your weight within therecommended BMI limit. There are numerous hormone and lifestyle-related issues, which lead to abnormal weight. Have a regular exercise schedule, maintain a balanced diet and take proper medical care for any underlying problems to reduce weight.

Heavy smoking and drinking can alter energy levels and reduce sex drive. Moderate alcohol consumption will not affect your libido but, smoking can have a tremendous negative effect. Smoking is also linked with insomnia and other problems. Try reducing your cigarette and alcohol consumption. If required, join therapies or any other recreational programs to keep you away from these habits.

In certain cases, some medicines that you consume can reduce your libido considerably. It might be a side effect that is caused by those medicines. If you are consuming any life-saving medications, it is best to not avoid medicine. However, this low sex drive is temporary and you would regain it after stopping the medicine.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

Continued here:
How to Naturally Boost Libido Instead of Pills - Nature World News

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who have completed adjuvant trastuzumab-based therapy less than one year ago.

The rapid and smooth advancement of NERLYNX through the Hong Kong regulatory process to market approval is a testament to the quality of our regulatory expertise, and the CANbridge commitment to bring new treatments to underserved patient populations in greater China, said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. With this first targeted therapy approved in our oncology platform, CANbridge is able to provide women in Hong Kong, with HER2-positive breast cancer at risk of recurrence, a new and vital treatment option shortly after approval in the West.

Alan H. Auerbach, Puma Biotechnologys Chairman, Chief Executive Officer and President, added, This registration approval through our partnership with CANbridge represents an important market entry for us as we execute on our global commercial strategy. CANbridge has the commercial infrastructure and resources to provide NERLYNX to patients in the region.

About HER2-Positive Breast Cancer

Approximately 20 to 25 percent of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

About CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been widely recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In addition, it has an exclusive licensing agreement to commercialize Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnologys NERLYNX (neratinib), approved in the United States, and rights to other novel candidates.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in August 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Important Safety Information Regarding NERLYNX (neratinib) U.S. Indication

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions ( 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the worldwide expansion of NERLYNX. All forward-looking statements involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2018. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Visit link:
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX (neratinib) for Extended...

With her glowing complexion and enviable figure, Carol Vorderman is as stunning now as she was when she first found fame on Channel 4's Countdown in 1982.

Filling in for Lorraine Kelly on her ITV show today, fans were in awe of her smooth visage, with many asking what her secret is.

And the star - who will present the The Daily Mirror Pride of Britain Awards tonight on ITV at 8pm - previously revealed she's a big fan of treatments such as plasma showers, which used ionised gas to strip bacteria from the skin and encourage the growth of new cells.

She hasn't been under the knife but does have botox injections once a year in her neck and around her eyes.

She also has derma roller treatment, whereby micro-needles are rolled across the skin to stimulate collagen.

She also tackles her looks from the inside out, taking vitamins A and D, omega 3, fish oils, calcium, pro-biotics and cider vinegar.

"And I eat well. I cut down on sugar and cut down on carbs long before it became fashionable, and most of the week I drink very little alcohol. Your tolerance goes down after the menopause. Two glasses of wine and I feel it the next day. But I do love to party!" she told the Daily Mail.

Then there's that sensational figure.

To maintain her 25-inch waist, Carol - who hasn't weighed herself since 1999 - does a staggering 15,000 steps a day and hikes more than 50 miles a week.

She also hits the gym three days out of seven and does three open-air circuit training sessions.

"Im probably about a size 8 to 9 at the moment. Ive always had a small waist, I think Im about 25 inches around my waist. If I put on a bit of weight, I know I have, and I go up to a size 11," she recently told Lorraine.

"A larger size 10, thats kind of my boundary for where Im happy."

As for her award-winning bottom - which won Rear of the Year in 2011 and 2014 and earned her Kim Kardashian comparisons - that, too, is hard-earned.

"I promise I havent had bottom implants. Its the same old bottom. In my family, loads of us have it: the Vorderman a**e... And Ive been working out for decades, so the shape of mine is down to years of keeping fit," she told the Daily Mail.

To achieve her look, she does 20,000 squats a year and is a huge fan of 'goblet squats' with a kettle bell.

Carol started using hormone replacement therapy three years ago and believes that has also changed the shape of her body, increasing her bust from a size 36 to a 38D.

"I think your bust does grow with hormonal changes. And we all know you put on weight when your bust grows. You have babies; it grows. Then you go through the menopause - I had my last period about a year ago - and it grows a bit more," she added.

* Watch the Daily Mirror's Pride Of Britain Awards now on the ITV Hub

Read more:
Secrets of Pride of Britain Carol Vorderman's ageless beauty and that 25-inch waist - Irish Mirror

Future Market Insights has recently published a report titledAnti-Osteoporosis Therapy and Fracture Healing Market: Global Industry Analysis (2012 2017) and Opportunity Assessment (2018 2026).The report states that despite the uncertainty in terms of political and economic scenario, the global healthcare industry is expected to receive a positive push from sectors such as medical imaging, in-vitro diagnostics, biotech and pharmaceuticals, and medical devices. Key markets across the world are facing an enormous rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits. A speedily multiplying geriatric population, growing prevalence of chronic ailments such as cancer and cardiac disease, rising awareness among patients and high investments in clinical innovation are a few of the factors that are impacting the performance of the global healthcare industry at present. As a result of these factors, the globalanti-osteoporosis therapy and fracture healing marketis expected to witness a CAGR of 5.0% between 2018 and 2026.

Growing Geriatric Population to Augur Adoption

Rising prevalence of osteoporosis is considered to be an important factor driving the global market, as the growing number of patients will also increase the demand for drugs and therapy. Furthermore, due to the absence of any substitutes such as surgery, demand for osteoporosis drugs is increasing constantly. According to the International Osteoporosis Foundation, almost 50% of the global bone fracture incidences would occur in the Asia Pacific region by 2050 end. A high occurrence and incidence rate of the disease is considered an important driver for the market. Furthermore, rising geriatric population is considered to be an important factor for the growth of the market in the coming years, although patent expiries of leading brands would considerably slow down the growth rate.

Download sample copy of this report:https://www.futuremarketinsights.com/reports/sample/REP-GB-1008

Bisphosphonates to Lead Among Drug Types

The global anti-osteoporosis therapy and fracture healing market has been segmented on the basis of drug type into bisphosphonates, calcitonin, estrogen or hormone replacement therapy, biologics, and anabolics. Among these, bisphosphonates is expected to emerge dominant by the end of 2026 with a valuation of around US$ 5,941 Mn in the same year.

Download Methodology :https://www.futuremarketinsights.com/askus/rep-gb-1008

Companies to Fight for Patent Rights

Leading companies in the market are competing against each other to gain patent rights on the different novel drugs that are being introduced in the market. This is further expected to intensify competition in the global market in the long run. Some of the companies operating in the global anti-osteoporosis therapy and fracture healing market are Novartis, Johnson and Johnson, GlaxoSmithKline PLC, Roche, Pfizer, MERCK, and AMGEN, among others.

For more detailed information and insights on the global anti-osteoporosis therapy and fracture healing market, contact Future Market Insights analysts at[emailprotected]

Buy this report @:https://www.futuremarketinsights.com/checkout/1008

Original post:
Anti-Osteoporosis Therapy and Fracture Healing Market to Record CAGR of 5% Rise in Growth by 2026 - Maxi Wire

Then came another blow. Ms Beatriz was diagnosed as being among the 10 percent of Australian women experiencing early menopause.

Loading

My first reaction was to cry because having kids was something that I had wanted forever and I felt such grief about it," Ms Beatriz, now 28, said. "I felt very alone. I was going through something nobody else in my friendship group had experienced."

Menopause before the age 45 is referred to as "early menopause". Onset can be spontaneous and sometimes unexplained. For about five per cent of women the cause remains unknown.

The isolation experienced by these women can be profound, says Monash University endocrinologist Associate Professor Amanda Vincent, and there is a lack of credible and high-quality information available.

This prompted researchers at Monash University and RMIT to collaborate on a digital platform that shares the stories of 30 women, aged between 28 and 51, who have experienced early menopause.

The Healthtalk Australia website, to be launched on Monday, also includes support services for women and information for health professionals about diagnosing the condition, including symptoms, treatments and long-term effects.

"Early menopause can lead to infertility, psychological distress and increased risks of bone and heart disease. It can also be a very lonely," Associate Professor Vincent said. "It can impact on their feeling of feminity and women affected have told us heartbreaking stories about their experiences."

Associate Professor Vincent said the website would also aim to spark conversations about early menopause.

About 25 per cent of women with breast cancer, uterine or ovarian cancer are pre-menopausal at diagnosis and it is believed there are more women experiencing early menopause due to higher cancer survivalrates.

"The whole experience of 'I am not alone, other women gone through this' can be really helpful for women going through this transition," Associate Professor Vincent said.

Loading

Ms Beatriz's boyfriend at the time of her diagnosis broke up with her after finding out she would not be able to conceive.

She later lost two jobs as she struggled to control her often debilitating symptoms and the side effects of using different doses of hormone replacement therapiesto regulate her body.

"The hardest part was feeling like nobody understood what I was going through," Ms Beatriz said.

Menopausal hormone therapyis currently the most effective type of treatment available for perimenopause symptoms, with more than 300,000 Australian women using it.

But it is not without controversy. Studies have linked it to a slightly increased risk of developing cancer in women who have gone through menopause at the expected age.

Dr Elizabeth Farrell, a gynaecologist and medical director of Jean Hailes for Women's Health, said hormone therapy was critical for women experiencing premature menopause as it helped reduce the heightened risk of developing conditions including cardiovascular disease, heart disease and osteoporosis.

"These women, for their blood vessels, bones and general well-being, need reasonably high doses of [hormone] therapy because that's what their bodies would normally have," Dr Farrell said. "We need to normalise their bodies to protect them until they reach the expected age of menopause."

Dr Farrell said research suggested young women using hormone therapy have about the same chance of developing breast or ovarian cancer as women the same age who are not using it and still menstruating.

Melissa Cunningham is The Age's health reporter.

See the original post here:
'My first reaction was to cry': Lorena showed signs of menopause at 25 - Sydney Morning Herald